August 24, 2019 posted by

Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Yozshusida Meztikora
Country: Greece
Language: English (Spanish)
Genre: Technology
Published (Last): 12 September 2005
Pages: 79
PDF File Size: 4.65 Mb
ePub File Size: 3.22 Mb
ISBN: 923-4-73287-385-5
Downloads: 80763
Price: Free* [*Free Regsitration Required]
Uploader: Golticage

Bennett M, Schechter GP. The cases that we presented here allowed us to observe that even in these situations, the use of rituximab monotherapy might be a valid option when postponement of cytotoxic chemotherapy is an issue. SMZL is an indolent lymphoma usually treated by splenectomy. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.

N Engl J Med.

The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style. From our search in the PubMed database using the terms ” rituximab AND marginal zone B cell lymphoma AND therapy”, espleinco found papers, of which six were related to the current topic.

Patients with asymptomatic disease are generally managed using a watch-and-wait strategy, while the majority of symptomatic individuals undergo splenectomy or splenic irradiationand a few receive front-line chemotherapy, especially with purine analogues. References of trials included in systematic review Reference 2 in.


LEZM – Linfoma Esplénico de la Zona Marginal

CiteScore measures average citations received per document published. The current WHO classification of lymphoid neoplasms represents a major step forward in our understanding of these tumours.

The median clinical remission interval was 46 months. One CR and seven minor or good haematological esponses were recorded in relapsed patients. Subscriber If you already have your login data, please click here. Rituximab should be considered in patients who are poor candidates for splenectomy.

Marginla objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or 11 Grupo Asturiano de Linfomas Noviembre chemotherapy alone.

RT PCR para t 11; Deoxycoformycin pentostatin in the treatment of splenic marginal zone lymphoma SMZL with or without villous lymphocytes. Here, we reported on two cases of patients who underwent splenectomy and then presented disease progression after the procedure, but who showed an impressive response to rituximab monotherapy as a rescue treatment.

The diagnosis was established using standard criteria. Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis.

It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject. SMZL was confirmed in 70 patients. In the year has been indexed in fsplenico Medlinedatabase, and has become a vehicle for expressing the most current Spanish medicine and modern.


However, considering the indolent course of SMZL, the therapeutic decision should be directed towards less toxic agents. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.

Ten additional patients underwent splenectomy, and 17 patients were in the observation group. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma.

Procesos linfoproliferativos no Hodgkin de células B

Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Interestingly, in addition to a relevant percentage of hematological remission, some patients also experienced a molecular remission.

Nodal marginal zone lymphoma: You can change the settings or obtain more information by clicking here. Deleciones de 13q14, distales al gen de retinoblastoma.

Recientes estudios parecen confirmar la heterogeneidad molecular de este conjunto de enfermedades. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. No respuesta o enfermedad progresiva: Cutaneous presentation of follicular lymphomas. Extramedullary tumors of lymphoid or myeloid blasts. Rituximab monotherapy for splenic marginal zone lymphoma. Skin biopsy showed an epidermotropic lymphocytic infiltration and cytology and immunohistochemistry were consistent with MZL.

Linfoma esplénico de la zona marginal:

Si continua navegando, consideramos que acepta su uso. Two out three patients, who received pentostatin as first line therapy, ttained a complete response CR.

Only comments seeking to improve the quality and accuracy of oinfoma on the Orphanet website are accepted.